A Phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (EPd) or pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in participants with relapsed/ refractory multiple myeloma who received prior anti-CD38 directed therapy.
Principal investigator: Juha Lievonen
HUS, Helsinki University Hospital, Comprehensive Cancer Center
Link to the Clinical Trials.gov website
